Biomea Fusion BMEA
NASDAQ BMEA
$1.37 +0.01 (+0.74%)
At close: Aug 21, 2026 · 4:00 PM EDT

Biomea Fusion (BMEA) Income towards Parent Company (2020 - 2026)

Biomea Fusion (BMEA) posted Income towards Parent Company of -$12.3 million for Q1 2026, up 26.95% sequentially from -$16.9 million in Q4 2025, and up 57.82% YoY from -$7.8 million in Q1 2025.

Biomea Fusion (BMEA) Income towards Parent Company (2020 - 2026) Analysis & Trends

Biomea Fusion has reported Income towards Parent Company for 7 years, with the latest figure at -$12.3 million in Q1 2026.

  • Quarterly Income towards Parent Company rose 57.82% year-over-year to -$12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.4 million (up 48.43% YoY) and the FY2025 annual result came in at -$214.9 million, up 14.82% from the prior year.
  • Income towards Parent Company improved to -$12.3 million in Q1 2026 per BMEA's latest filing, from -$16.9 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$12.3 million in Q1 2026 and troughed at -$45.3 million in Q3 2023.
  • A 5-year average of -$27.9 million and a median of -$29.3 million in 2025 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2023 and 2026: Income towards Parent Company slumped 145.42% in 2023, then surged 57.82% in 2026.
  • Over 5 years, Income towards Parent Company stood at -$25.5 million in 2022, then plunged by 35.3% to -$34.5 million in 2023, then grew by 14.68% to -$29.4 million in 2024, then jumped by 42.56% to -$16.9 million in 2025, then grew by 26.95% to -$12.3 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$12.3 million, -$16.9 million, and -$16.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Biomea Fusion 97.69 Mn 97.69 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2026 -12.45 Mn
Mar 31, 2026 -12.34 Mn
Dec 31, 2025 -16.90 Mn
Sep 30, 2025 -16.41 Mn
Jun 30, 2025 -20.74 Mn
Mar 31, 2025 -29.26 Mn
Dec 31, 2024 -29.42 Mn
Sep 30, 2024 -32.79 Mn
Jun 30, 2024 -37.28 Mn
Mar 31, 2024 -43.30 Mn
Dec 31, 2023 -34.48 Mn
Sep 30, 2023 -45.34 Mn
Jun 30, 2023 -42.79 Mn
Mar 31, 2023 -29.89 Mn
Dec 31, 2022 -25.49 Mn
Sep 30, 2022 -23.07 Mn
Jun 30, 2022 -17.43 Mn
Mar 31, 2022 -16.54 Mn
Dec 31, 2021 -14.86 Mn
Sep 30, 2021 -15.99 Mn